This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impax Laboratories Inc (IPXL)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) 57.35M 101.26M 55.87M 65.50M
Operating Gains/Losses 54.21M 6.62M -34.28M -81.14M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -33.50M -20.74M 61.52M -71.88M
(Increase) Decrease in Inventories -24.30M 7.09M -35.59M -9.63M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -8.98M 4.70M 24.12M -2.04M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 500.00K 5.55M 3.25M 2.25M
Other Non-Cash Items -23.95M 38.89M -18.04M 88.65M
Net Cash From Continuing Operations 32.82M 149.94M 106.21M 6.36M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 32.82M 149.94M 106.21M 6.36M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 395.40M 285.99M 296.57M 375.13M
Purchases of Property, Plant & Equipment -42.91M -44.78M -171.66M -30.52M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -366.09M -357.09M -210.69M -359.65M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -16.60M -115.89M -85.78M -15.04M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 11.10M 8.21M 12.61M 14.77M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 3.32M 749.00K 4.70M 6.54M
Net Cash From Financing Activities 14.41M 8.96M 17.32M 21.31M
Effect of Exchange Rate Changes -369.00K -561.00K 0.00 0.00
Net Change in Cash & Cash Equivalents 30.26M 42.45M 37.74M 12.62M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

IPXL Impax Laboratories Inc

Chart of IPXL

Analysts Ratings for IPXL

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 1 1
Hold 5 5 5 6
Moderate Sell 1 1 1 1
Strong Sell 1 1 1 1

IPXL Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs